Business Description
TherapeuticsMD Inc
NAICS : 325412
SIC : 2834
ISIN : US88338N1072
Total Employee Number:
1Description
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.65 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -1.4 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -33.62 | |||||
Beneish M-Score | -3.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -67.3 | |||||
3-Year FCF Growth Rate | -39.6 | |||||
3-Year Book Growth Rate | -14.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.75 | |||||
9-Day RSI | 69.21 | |||||
14-Day RSI | 64.54 | |||||
3-1 Month Momentum % | 1.72 | |||||
6-1 Month Momentum % | -5.85 | |||||
12-1 Month Momentum % | 86.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.22 | |||||
Quick Ratio | 3.22 | |||||
Cash Ratio | 1.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 4.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -117.8 | |||||
Net Margin % | -6.64 | |||||
EBITDA Margin % | -121.25 | |||||
FCF Margin % | 96.37 | |||||
OCF Margin % | 96.37 | |||||
ROE % | -0.8 | |||||
ROA % | -0.57 | |||||
ROIC % | -13.22 | |||||
3-Year ROIIC % | 43.36 | |||||
ROC (Joel Greenblatt) % | -106.34 | |||||
ROCE % | -16.97 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.44 | |||||
PS Ratio | 7.87 | |||||
PB Ratio | 0.95 | |||||
Price-to-Tangible-Book | 1.09 | |||||
Price-to-Free-Cash-Flow | 8.22 | |||||
Price-to-Operating-Cash-Flow | 8.22 | |||||
EV-to-EBIT | -3.93 | |||||
EV-to-EBITDA | -5.57 | |||||
EV-to-Revenue | 6.75 | |||||
EV-to-Forward-Revenue | 0.95 | |||||
EV-to-FCF | 7.01 | |||||
Price-to-GF-Value | 1.07 | |||||
| Price-to-Net-Current-Asset-Value | 4.56 | |||||
Earnings Yield (Greenblatt) % | -25.45 | |||||
FCF Yield % | 12.26 |
TherapeuticsMD Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TherapeuticsMD Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-15 08:00 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 76 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 1.76 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.64 (-1.20%) | ||
| Annual report for 2025 | 2026-03-30 | 1.80 (-4.76%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.80 (-4.76%) | ||
| General meeting for 2025 | 2025-12-15 08:00 | 1.53 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.14 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 0.92 (+2.79%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 1.32 (+3.94%) |
Show
Entries
Press Release
Articles on TherapeuticsMD Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers